Login to Your Account


Promedior highlights favorable data on myelofibrosis therapy

By Michael Fitzhugh
Staff Writer

Friday, May 30, 2014
Positive preliminary data from a phase II trial of Promedior Inc.'s experimental myelofibrosis therapy, PRM-151, showed the anti-fibrotic immunotherapy to be safe, well tolerated and effective in reducing symptoms of the disease. The small open-label, prospective study demonstrated improvements in bone marrow fibrosis, hemoglobin levels, platelet count, spleen volume and symptoms, painting a promising picture said Promedior president and CEO Suzanne Bruhn, a veteran of Dublin-based Shire plc. The Lexington, Mass.-based company is excited to have early evidence of PRM-151's ability to target the foundations of fibrosis and validation of its potential to treat and reverse fibrotic diseases.

To continue reading subscribe now to Science News

Learn More about Science News

Already a subscriber? Sign In or Buy now to activate your subscription